| Name | Title | Contact Details |
|---|---|---|
Patrick Baumhof |
Senior Vice President of Technology | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.
AmerisourceBergen Drug Corporation is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humanetics Corp. is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.